| Feb 7 2020 |
BRAG Biobased Products Blog: February 7, 2020 |
Bergeson & Campbell, P.C. |
| Feb 7 2020 |
California Proposes Amendments to Proposition 65 Warning Regulations |
Keller and Heckman LLP |
| Feb 7 2020 |
Ninth Circuit Confirms Dr Pepper Can Stick to its “Diet” |
Proskauer Rose LLP |
| Feb 7 2020 |
EPA Issues Interim Registration Review Decision for Glyphosate |
Bergeson & Campbell, P.C. |
| Feb 6 2020 |
2020 Digital Health Outlook: Thoughts from CES and JPM [Podcast] |
McDermott Will & Schulte LLP |
| Feb 6 2020 |
Method of Treatment Efficacy Benchmarks Avoid Inherency Attack |
Schwegman, Lundberg & Woessner, P.A. |
| Feb 6 2020 |
30,000 Cannabis Users’ Data Exposed |
Robinson & Cole LLP |
| Feb 6 2020 |
Washington State Lawmakers Sponsor Bill Requiring Retailers to Mark Meat as Either “USA Beef” or “Imported” |
Keller and Heckman LLP |
| Feb 6 2020 |
The DNA Entertainment Complex and its Pitfalls |
Womble Bond Dickinson (US) LLP |
| Feb 6 2020 |
Wuhan Institute of Virology Applies for a Patent on Gilead’s Remdesivir |
Schwegman, Lundberg & Woessner, P.A. |
| Feb 5 2020 |
DC Council Committee Votes to Ban Retail Sale of Polystyrene Products |
Keller and Heckman LLP |
| Feb 5 2020 |
Turkey’s New Plastic Food-Contact Regulations Align with EU Plastics Regulation |
Keller and Heckman LLP |
| Feb 5 2020 |
FDA Approves Drug to Treat Peanut Allergy in Children |
Keller and Heckman LLP |
| Feb 5 2020 |
Agencies’ Antitrust Suit Against Drug Maker Underscores Challenges of Bringing Biosimilars to Market |
MoginRubin |
| Feb 4 2020 |
2019 IP Law Year In Review – Trademarks |
McDermott Will & Schulte LLP |
| Feb 4 2020 |
Will the Coronavirus Make Your Business Sick? |
Much Shelist, P.C. |
| Feb 4 2020 |
Hierarchy of Scientific Evidence Reigns Supreme: NJ Appellate Division Affirms Exclusion of Experts in Accutane Litigation |
Faegre Drinker |
| Feb 4 2020 |
New Government Action Aims to Increase Competition among Biological Products: FDA and FTC Step Up Industry Pressure |
Mintz |
| Feb 4 2020 |
Anticompetitive Conduct in Biologics – An Enforcement Priority with FTC and FDA |
McDermott Will & Schulte LLP |
| Feb 4 2020 |
Nanotechnology Entrepreneurship Network Webinar on Insights from the U.S. Patent and Trademark Office Will Be Held February 5 |
Bergeson & Campbell, P.C. |
| Feb 4 2020 |
In the Wake of Heightened Regulatory Scrutiny of Vaping Products, Nicotine-Containing Toothpicks are Next to Come Under Fire by FDA |
Keller and Heckman LLP |
| Feb 4 2020 |
GAO Recommends CMS, HRSA Improve 340B Duplicate Discount Oversight |
McDermott Will & Schulte LLP |
| Feb 3 2020 |
Intellectual Property Outlook: Cases and Trends to Follow in 2020 — PART 2 |
Sheppard, Mullin, Richter & Hampton LLP |
| Feb 3 2020 |
CMS’s Healthy Adult Opportunity: What You Need to Know |
McDermott Will & Schulte LLP |
| Feb 3 2020 |
FDA User Fees: Highlights from FDARA & Our Forecast for the Next Round |
Mintz |
| Feb 3 2020 |
USDA AMS Solicits Comments on Draft Instructions for Testing Methods to Confirm the Absence of Detectable Modified Genetic Material |
Keller and Heckman LLP |
| Feb 3 2020 |
Opioid Update: MDL Defendants Return to the Sixth Circuit |
Squire Patton Boggs (US) LLP |
| Feb 1 2020 |
EPA Responds to Coronavirus Cases |
Bergeson & Campbell, P.C. |
| Jan 31 2020 |
Food Contact Materials: What Are Your Legal Responsibilities? |
Keller and Heckman LLP |
| Jan 31 2020 |
HazCom/GHS - Labelling – Multi-Jurisdictional Labels - Different Classification OR Supplemental Information |
Keller and Heckman LLP |
| Jan 31 2020 |
McDermottPlus Check-Up: January 31, 2020 |
McDermott Will & Schulte LLP |
| Jan 31 2020 |
Comments on Chapter 14: Recall Plan of FDA’s Draft Guidance on Human HARPC Rule Due February 4 |
Keller and Heckman LLP |
| Jan 30 2020 |
DEA’s National Drug Threat Assessment Shows Marijuana Potency and Demand Increasing; Black Market Operations Thriving |
Jackson Lewis P.C. |
| Jan 30 2020 |
USDA’s Hemp Production Program Advances |
Squire Patton Boggs (US) LLP |
| Jan 30 2020 |
OIG Advisory Opinion Permits a Pharmaceutical Manufacturer to Provide Financial Assistance to Needy Patients Receiving Risky Cell Therapy |
Mintz |
